X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA ABBOTT INDIA ELDER PHARMA/
ABBOTT INDIA
 
P/E (TTM) x -0.2 41.2 - View Chart
P/BV x 0.1 9.8 1.0% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ELDER PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
ABBOTT INDIA
Mar-18
ELDER PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs3806,110 6.2%   
Low Rs1883,996 4.7%   
Sales per share (Unadj.) Rs491.21,552.2 31.6%  
Earnings per share (Unadj.) Rs-3.2188.8 -1.7%  
Cash flow per share (Unadj.) Rs14.4196.4 7.3%  
Dividends per share (Unadj.) Rs055.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs376.5796.6 47.3%  
Shares outstanding (eoy) m20.5421.25 96.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.3 17.8%   
Avg P/E ratio x-89.326.8 -333.5%  
P/CF ratio (eoy) x19.725.7 76.6%  
Price / Book Value ratio x0.86.3 11.9%  
Dividend payout %029.1 0.0%   
Avg Mkt Cap Rs m5,833107,376 5.4%   
No. of employees `000NA3.3 0.0%   
Total wages/salary Rs m2,1793,937 55.3%   
Avg. sales/employee Rs ThNM9,929.3-  
Avg. wages/employee Rs ThNM1,185.1-  
Avg. net profit/employee Rs ThNM1,207.7-  
INCOME DATA
Net Sales Rs m10,08932,985 30.6%  
Other income Rs m2571,170 21.9%   
Total revenues Rs m10,34634,155 30.3%   
Gross profit Rs m-7925,245 -15.1%  
Depreciation Rs m361162 223.2%   
Interest Rs m2,75638 7,215.4%   
Profit before tax Rs m-3,6536,215 -58.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1252,203 5.7%   
Profit after tax Rs m-654,012 -1.6%  
Gross profit margin %-7.815.9 -49.4%  
Effective tax rate %-3.435.4 -9.7%   
Net profit margin %-0.612.2 -5.3%  
BALANCE SHEET DATA
Current assets Rs m9,24022,655 40.8%   
Current liabilities Rs m9,9986,681 149.6%   
Net working cap to sales %-7.548.4 -15.5%  
Current ratio x0.93.4 27.3%  
Inventory Days Days4665 71.5%  
Debtors Days Days6029 205.6%  
Net fixed assets Rs m10,124835 1,211.7%   
Share capital Rs m206213 96.8%   
"Free" reserves Rs m5,58216,715 33.4%   
Net worth Rs m7,73416,928 45.7%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88224,162 94.7%  
Interest coverage x-0.3163.7 -0.2%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.41.4 32.3%   
Return on assets %11.816.8 70.2%  
Return on equity %-0.823.7 -3.6%  
Return on capital %22.336.9 60.4%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m307369 83.2%   
Fx outflow Rs m1253,807 3.3%   
Net fx Rs m181-3,438 -5.3%   
CASH FLOW
From Operations Rs m11,7541,527 769.8%  
From Investments Rs m-561-2,148 26.1%  
From Financial Activity Rs m-6,762-1,024 660.1%  
Net Cashflow Rs m4,432-1,646 -269.3%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.5 7.9 94.9%  
FIIs % 16.8 0.1 16,800.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 17.1 211.1%  
Shareholders   16,479 18,270 90.2%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   BIOCON LTD  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  FDC LTD.  

Compare ELDER PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (4QFY18); Net Profit Up 137.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 137.9% YoY). Sales on the other hand came in at Rs 8 bn (up 10.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS